Science Magazine | AAAS: Science Translational Medicine Follow NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors | Science Translational Medicine Coactivation of ER and RAS signaling in NF1-depleted ER+ breast cancer promotes CDK4 activation and endocrine therapy resistance https://www.science.org/doi/10.1126/scitranslmed.adq5492 science.org
